February 24, 2018 4:12 PM ET

Biotechnology

Company Overview of IFM Therapeutics, Inc.

Company Overview

IFM Therapeutics, Inc., a biopharmaceutical company, develops a portfolio of small molecules targeting the innate immune system for the treatment of cancer and inflammatory disorders. It focuses on transformative therapies to improve the lives of patients with serious and life threatening diseases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts with a subsidiary in Bonn, Germany. As of September 7, 2017, IFM Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

400 Technology Square

10th Floor

Cambridge, MA 02139

United States

Founded in 2015

Key Executives for IFM Therapeutics, Inc.

Co-Founder, CEO & Director
Co-Founder
Co-Founder
Co-Founder
Compensation as of Fiscal Year 2017.

IFM Therapeutics, Inc. Key Developments

IFM Therapeutics LLC Appoints Dr. Michael Heneka to Clinical Advisory Board

IFM Therapeutics, LLC announced the appointment of Dr. Michael Heneka to its clinical advisory board. Heneka, who serves as Director of the Department of Neurodegenerative Diseases and Gerontopsychiatry at the University Hospital of Bonn, Germany, will join a group of seven distinguished immunotherapy pioneers on the IFM Therapeutics clinical advisory board.

IFM Therapeutics, LLCAppoints William R. Roush as Executive Vice President of Chemistry

IFM Therapeutics, LLC announced that William R. Roush, Ph.D., will join the company as executive vice president of chemistry. Roush joins IFM after having originally served as a senior advisor of the company. In his new role, Roush will oversee IFM's chemistry efforts aimed at discovering and developing drugs that target the innate immune system. Roush joins IFM from The Scripps Research Institute where he served as a professor of chemistry, executive director of medicinal chemistry and associate dean of Scripps' Kellogg Graduate School.

IFM Therapeutics Names H. Martin Seidel as Executive Vice President of Research and Development

IFM Therapeutics announced that H. Martin Seidel will be joining the company as Executive Vice President of Research and Development. In this new role, Seidel will be responsible for the development, expansion, and oversight of IFM's pipeline. Seidel brings deep experience in business development, drug discovery and strategy. He joins IFM from Novartis, where he was most recently the Global Head of Strategic Alliances for the Novartis Institutes for Biomedical Research.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
August 3, 2017
--
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
NYC2012, Inc. United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact IFM Therapeutics, Inc., please visit ifmthera.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.